Update in indolent non-hodgkin lymphoma (NHL): Paradigm for Waldenström's macroglobulinemia (WM)

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 1, 2011, Pages 149-151

  Chiappella, Annalisa ^a   Ciochetto, Chiara ^a   Orsucci, Lorella ^a   Vitolo, Umberto ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b Azienda Ospedaliero Universitaria San Giovanni Battista di Torino   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; LENALIDOMIDE; MITOXANTRONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; OBINUTUZUMAB; OFATUMUMAB; OXALIPLATIN; PREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; FOLLICULAR LYMPHOMA; HUMAN; LYMPHOCYTOMA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; SALVAGE THERAPY; WALDENSTROEM MACROGLOBULINEMIA; WATCHFUL WAITING;

EID: 79953678678     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2011.n.035     Document Type: Conference Paper

References (25)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, edn 4.Lyon, France: International Agency for Research on Cancer; 2008.
2. Federico M, Molica S, Bellei M, et al. Prognostic factors in low-grade non Hodgkin's lymphomas. Curr Hematol Malign Reports 2009; 4:2002-10.
3. Vitolo U, Ferreri AJ, Montoto S. Follicular lymphomas. Crit Rev Oncol Hematol 2008; 66:248-61.
4. Treon SP. How I treat Waldenstrom macroglobulinemia. Blood 2009; 114:2375-85.
5. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362:516-22. (Pubitemid 36976715)
6. Barosi G, Carella A, Lazzarino M, et al. Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2005; 90:1236-57.
7. NCCN Clinical Practice Guidelines in Oncology. Non Hodgkin's Lymphomas. V.I.2010.Available at: http://www.nccn.org.
8. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26:4579-86.
9. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725-32. (Pubitemid 41742196)
10. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25:1986-92. (Pubitemid 46972781)
11. Salles G, Mounier N, De Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112:4824-31.
12. Vitolo U, Ladetto M, Boccomini C, et al. Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial. Blood 2008; 112:834.
13. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany).Blood 2009; 114:405.
14. Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010; 10:21-7.
15. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26:5156-64.
16. Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111:4004-13.
17. Salles G, Catalano J, Feugier P, et al. Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: Results of the PRIMA study. Haematologica 2010; 95(suppl 2):229 (abstract 0557).
18. Dreyling M, Hiddemann W, European MCL Network. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009:542-51.
19. O'Connor OA, Moskowitz C, Protlock C, et al. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br J Haematol 2009; 145:34-9.
20. De Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009; 27:5023-30.
21. Chiappella A, Pregno P, Zinzani PL, et al. Efficacy and safety of bortezomib and rituximab association in relapsed/refractory indolent non-follicular and mantle cell lymphoma: final results of phase II study by Intergruppo Italiano Linfomi. Haematologica 2010; 95(suppl 2):106 (abstract 0271).
22. Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:5404-9.
23. Fowler NH, McLaughlin P, Hagemeister FB, et al. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 2010; 28:8036.
24. Fowler NH, McLaughlin P, Hagemeister FB, et al. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 2010; 28:8036.
25. Leonard JP,Schuster SJ,Emmanouilides C,et al; Durable complete responses from therapy with combined epratuzumab and rituximab final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer;2008,113; 2714-2723